Source comparison
CJC-1295 No DAC & Ipamorelin: Research Protocol Comparison
8–12 weeks 3–5x weekly, 100–200mcg each peptide Improved recovery markers, lean mass retention, sleep quality enhancement Mild water retention (12–18%), transient injection site reaction (8%), fasting glucose +3–5 mg/dL Optimal for initial assessment. Allows b
This comparison does not assign a generated winner or score.
- 8–12 weeks
- 3–5x weekly, 100–200mcg each peptide
- Improved recovery markers, lean mass retention, sleep quality enhancement
- Mild water retention (12–18%), transient injection site reaction (8%), fasting glucose +3–5 mg/dL
- Optimal for initial assessment. Allows baseline response evaluation without long-term commitment
- 12–24 weeks
- 2–3x weekly with 1-week monthly break
- Sustained body composition changes, maintained GH pulse amplitude
- Water retention stabilises (<5%), glucose tolerance requires monitoring if baseline impaired
- Standard research duration. Balances efficacy observation with manageable monitoring requirements
- 24+ weeks continuous
- 2x weekly, reduced dose (50–100mcg each)
- Diminishing returns after month 6 without cycling, receptor sensitivity decline possible
- Efficacy plateaus, risk of receptor desensitisation increases without washout periods
- Not recommended without planned 4–6 week breaks every 12–16 weeks to preserve receptor function
- Cyclic (12 weeks on, 4 weeks off)
- 3x weekly during active phase
- Preserves receptor sensitivity, maintains efficacy across multiple cycles
- Minimal. Side effects reset during off periods, metabolic markers return to baseline
- Preferred long-term approach. Maintains responsiveness while allowing physiological reset